RecruitingNCT03529617
Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
60 participants
Start Date
Oct 19, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Treatment with L-AmB
- Admitted to an ICU or Hematology ward
Exclusion Criteria3
- DNR 2 or 3
- Pregnant or lactating women
- Previous documentation of intolerance/sensitivity to L-AmB
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERSample collection
Plasma, urine, BAL and ascitic fluid sample collection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03529617
Related Trials
Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies
NCT046697171 location
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
NCT075601501 location
Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence VTI
NCT064864673 locations
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
NCT074222855 locations
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
NCT065007931 location